Volastra Therapeutics
BiotechnologyView the employees at
Volastra Therapeutics-
Arjun Balar Senior Vice President - Global Clinical Development; Loxo Oncology at Eli Lilly
-
New York City Metropolitan Area
-
Rising Star
Aliasghar Mortazi Sr Scientist at Volastra-
Rising Star
Derek Rookhuizen Senior Scientist, Volastra Therapeutics-
New York, New York, United States
-
Rising Star
Kenneth Hess Director, Business Development and Commercial at Volastra Therapeutics-
New York City Metropolitan Area
-
Rising Star
Jacqueline Campbell Sr. Clinical Project Manager-
New York, New York, United States
-
Rising Star
Overview
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
-